Lucid Diagnostics Inc. Stock Price, News & Analysis

Lucid Diagnostics (Nasdaq: LUCD) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.

Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one investor meetings; meetings must be scheduled through a Canaccord Genuity representative.

PAVmed (NASDAQ: PAVM) and subsidiaries Lucid Diagnostics (NASDAQ: LUCD) and Veris Health provided a business update and reported 3Q25 results on November 13, 2025. Key operating items: Lucid recognized $1.2M of EsoGuard revenue and processed 2,841 tests, and a Medicare Contractor Advisory Committee meeting showed unanimous expert support for Medicare coverage. Lucid completed an underwritten offering netting approximately $27.0M. Veris launched commercial deployment with OSU James and relaunched development of an implantable physiological monitor ahead of a planned 2026 510(k) submission. Financials: consolidated revenue was $5K for the quarter, GAAP net loss attributable to common stockholders was approximately $6.3M (loss per diluted share $(0.29)), non-GAAP adjusted loss was approximately $0.4M, and cash and cash equivalents totaled $3.1M.

Lucid Diagnostics (Nasdaq: LUCD) reported 3Q25 EsoGuard revenue of $1.2M from 2,841 tests processed, GAAP net loss of $10.4M (GAAP EPS $(0.10)), and non-GAAP adjusted loss of $10.3M ($(0.10) per share).

The company completed a public offering netting $27.0M, ended 3Q25 with $47.3M cash proforma, and said this extends runway through 2026 and past upcoming reimbursement milestones. A MolDx CAC meeting produced a unanimous expert consensus supporting Medicare coverage for EsoGuard, a key step in LCD reconsideration.

PAVmed (NASDAQ: LUCD) will host a business update conference call and webcast on November 13, 2025 at 8:30 AM ET. The call will feature Lishan Aklog, M.D., chairman and CEO, providing an overview of operations and growth strategy, and Dennis McGrath, president and CFO, discussing the company’s third quarter 2025 financial results.

The live webcast will be available in the investor relations section of pavmed.com. U.S. callers can join by dialing 1-800-836-8184; international listeners can dial 1-646-357-8785 and should request the conference name "PAVmed Business Update." A replay will be available on the investor relations website for 30 days after the call.

Lucid Diagnostics (Nasdaq: LUCD) will hold a business update conference call and webcast on Wednesday, November 12, 2025 at 8:30 AM ET. Management will include Lishan Aklog, M.D., chairman and CEO, who will provide a business update and growth strategy overview, and Dennis McGrath, CFO, who will discuss third quarter 2025 financial results. The webcast will be available in the investor relations section at luciddx.com. U.S. dial-in is 1-800-836-8184; international dial-in is 1-646-357-8785; ask the operator for the conference call name "Lucid Diagnostics Business Update" to join. A replay will be available for 30 days on the investor relations site.

Lucid Diagnostics (Nasdaq: LUCD) will participate in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025.

Dennis McGrath, Lucid's Chief Financial Officer, will hold one-on-one investor meetings during the conference; investors should contact their Maxim representative to schedule meetings. Registration and event details are available through the Maxim Growth Summit event page.

Lucid Diagnostics (Nasdaq: LUCD) has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs. Scelfo, a veteran with over 25 years of experience in healthcare policy and market access, will focus on expanding insurance coverage and patient access for the company's EsoGuard® Esophageal DNA Test.

The appointment comes at a crucial time following a positive MolDX CAC meeting that suggests Medicare coverage is approaching. Scelfo's previous experience includes leadership roles at ClearNote Health, CareDx, Hologic, and other prominent healthcare companies. She will leverage her expertise to strengthen Lucid's market access infrastructure and accelerate commercial coverage expansion.

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has completed its previously announced public offering. The company successfully sold 28,750,000 shares of common stock at $1.00 per share, which includes 3,750,000 shares from the full exercise of the underwriters' option.

The offering generated net proceeds of approximately $26.9 million, after deducting underwriting discounts, commissions, and estimated expenses. The funds will be used for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC as co-manager.

Lucid Diagnostics (NASDAQ: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), has announced the pricing of its public offering of 25 million shares of common stock at $1.00 per share.

The company expects to raise approximately $25.0 million in gross proceeds, with an additional 30-day option granted to underwriters to purchase up to 3.75 million additional shares. The offering, managed by Canaccord Genuity LLC and BTIG, LLC as joint bookrunners, is expected to close around September 11, 2025. Proceeds will be used for working capital and general corporate purposes.